Aponvie Now Available for Postoperative Nausea and Vomiting

aponvie (aprepitant) has been made available by Heron Therapeutics for the prevention of postoperative nausea and vomiting in adults.

Aponvie is an injectable emulsion formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. The formulation is identical to Heron’s approved drug product Cinvanti®, which is indicated for chemotherapy induced nausea and vomiting.

The safety and efficacy of Aponvie were established based on adequate and well-controlled studies of a single dose of oral aprepitant in adults. Additionally, a single 32mg dose of Aponvie was found to be bioequivalent to oral aprepitant 40mg in a phase 1 study.

Aponvie is supplied in a single-dose vial containing 32mg of aprepitant.

Related Content

Related Articles